JP2020512272A5 - - Google Patents

Download PDF

Info

Publication number
JP2020512272A5
JP2020512272A5 JP2019522244A JP2019522244A JP2020512272A5 JP 2020512272 A5 JP2020512272 A5 JP 2020512272A5 JP 2019522244 A JP2019522244 A JP 2019522244A JP 2019522244 A JP2019522244 A JP 2019522244A JP 2020512272 A5 JP2020512272 A5 JP 2020512272A5
Authority
JP
Japan
Prior art keywords
octadeca
diene
dimethylamino
bis
ethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019522244A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020512272A (ja
JP7075669B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IL2017/051212 external-priority patent/WO2018087753A1/en
Publication of JP2020512272A publication Critical patent/JP2020512272A/ja
Publication of JP2020512272A5 publication Critical patent/JP2020512272A5/ja
Application granted granted Critical
Publication of JP7075669B2 publication Critical patent/JP7075669B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019522244A 2016-11-08 2017-11-07 核酸送達用カチオン性脂質及びその調製物 Active JP7075669B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662418844P 2016-11-08 2016-11-08
US62/418,844 2016-11-08
US201762507829P 2017-05-18 2017-05-18
US62/507,829 2017-05-18
PCT/IL2017/051212 WO2018087753A1 (en) 2016-11-08 2017-11-07 Cationic lipids for nucleic acid delivery and preparation thereof

Publications (3)

Publication Number Publication Date
JP2020512272A JP2020512272A (ja) 2020-04-23
JP2020512272A5 true JP2020512272A5 (cg-RX-API-DMAC10.html) 2020-12-03
JP7075669B2 JP7075669B2 (ja) 2022-05-26

Family

ID=62109569

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019522244A Active JP7075669B2 (ja) 2016-11-08 2017-11-07 核酸送達用カチオン性脂質及びその調製物

Country Status (10)

Country Link
US (3) US11851389B2 (cg-RX-API-DMAC10.html)
EP (1) EP3538515B1 (cg-RX-API-DMAC10.html)
JP (1) JP7075669B2 (cg-RX-API-DMAC10.html)
CN (1) CN110167922B (cg-RX-API-DMAC10.html)
AU (1) AU2017356699B2 (cg-RX-API-DMAC10.html)
DK (1) DK3538515T3 (cg-RX-API-DMAC10.html)
ES (1) ES2928358T3 (cg-RX-API-DMAC10.html)
MX (1) MX2019005287A (cg-RX-API-DMAC10.html)
PT (1) PT3538515T (cg-RX-API-DMAC10.html)
WO (1) WO2018087753A1 (cg-RX-API-DMAC10.html)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108368028B (zh) 2015-10-28 2021-09-03 爱康泰生治疗公司 用于递送核酸的新型脂质和脂质纳米颗粒制剂
US12678515B2 (en) 2015-12-30 2026-07-14 Acuitas Therapeutics, Inc. Lipids and lipid nanoparticle formulations for delivery of nucleic acids
EP3484517B1 (en) 2016-07-18 2025-07-02 Ramot at Tel-Aviv University Ltd. Modular platform for targeted therapeutics
US12491261B2 (en) 2016-10-26 2025-12-09 Acuitas Therapeutics, Inc. Lipid nanoparticle formulations
ES2964547T3 (es) 2018-06-08 2024-04-08 Fujifilm Corp Compuesto, sal del mismo y partículas lipídicas
MX2021003726A (es) 2018-10-01 2021-05-13 BioNTech SE Particulas de arn que comprenden polisarcosina.
DK3864163T3 (da) 2018-10-09 2024-05-06 Univ British Columbia Sammensætninger og systemer omfattende transfektionskompetente vesikler fri for organiske opløsningsmidler og rengøringsmidler og fremgangsmåder forbundet dermed
CA3116576A1 (en) 2018-10-18 2020-04-23 Acuitas Therapeutics, Inc. Lipids for lipid nanoparticle delivery of active agents
CA3117924A1 (en) * 2018-11-13 2020-05-22 Oncorus, Inc. Encapsulated polynucleotides and methods of use
CN119285480A (zh) * 2018-12-05 2025-01-10 英特利亚治疗股份有限公司 改性的胺脂质
CA3143865A1 (en) * 2019-06-07 2020-12-10 Fujifilm Corporation Lipid composition
EP4059505B1 (en) * 2019-11-15 2024-02-21 FUJIFILM Corporation Lipid composition
US20230241223A1 (en) * 2020-03-25 2023-08-03 BioNTech SE Rna particles comprising polysarcosine
TWI899203B (zh) 2020-04-09 2025-10-01 大陸商蘇州艾博生物科技有限公司 脂質奈米粒子組成物
WO2021204179A1 (en) 2020-04-09 2021-10-14 Suzhou Abogen Biosciences Co., Ltd. Nucleic acid vaccines for coronavirus
EP4153560A4 (en) * 2020-05-19 2024-04-24 Ramot at Tel-Aviv University Ltd. LIPID PARTICLES FOR NUCLEIC ACID DELIVERY AND CLINICAL APPLICATIONS THEREOF
KR20230051172A (ko) 2020-07-16 2023-04-17 아퀴타스 테라퓨틱스 인크. 지질 나노 입자에 사용하기 위한 양이온성 지질
WO2022066916A1 (en) * 2020-09-23 2022-03-31 Translate Bio, Inc. Piperazine-based cationic lipids
CZ310613B6 (cs) * 2020-09-23 2026-01-28 Ústav organické chemie a biochemie AV ČR, v. v. i. Lipidoidy pro transfekci nukleových kyselin a jejich použití
WO2022112855A1 (en) * 2020-11-27 2022-06-02 Guangzhou Ribobio Co., Ltd Lipid compound and the composition thereof
KR20230138496A (ko) * 2021-02-02 2023-10-05 라모트 앳 텔-아비브 유니버시티 리미티드 핵산 전달에 적합한 지질
CN117327270B (zh) * 2021-04-08 2026-07-07 厦门赛诺邦格生物科技股份有限公司 一种聚乙二醇化脂质及其修饰的脂质体、含该脂质体的药物组合物及其制剂和应用
CN115197079A (zh) * 2021-04-08 2022-10-18 厦门赛诺邦格生物科技股份有限公司 一种聚乙二醇化脂质及其修饰的脂质体、含该脂质体的药物组合物及其制剂和应用
JP2024518689A (ja) * 2021-04-09 2024-05-02 ファイザー・インク 脂質を生産するための方法
JP2024516164A (ja) * 2021-04-22 2024-04-12 ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム 正確なインビボhdr介在性遺伝子編集を可能にするオールインワンデンドリマーベース脂質ナノ粒子
CA3215963A1 (en) * 2021-05-28 2022-12-01 Yaoxin LIN Lipid compound and use thereof in delivery of nucleic acid
EP4370134A4 (en) 2021-07-13 2025-08-06 Technion Res & Dev Foundation COMPOSITIONS AND METHODS FOR TREATING A HEALTH CONDITION
CZ310443B6 (cs) 2021-07-19 2025-06-25 Ústav organické chemie a biochemie AV ČR, v. v. i. Cyklohexanové lipidoidy pro transfekci nukleových kyselin a jejich použití
EP4365168B1 (en) 2021-07-23 2025-10-15 Jenkem Technology Co., Ltd. (Tianjin) Polyol-modified lipid compound and preparation method and application thereof
CN115010681A (zh) * 2021-09-07 2022-09-06 安徽荣灿生物科技有限公司 一类阳离子脂质体分子及其制备和应用
WO2023061460A1 (zh) * 2021-10-15 2023-04-20 厦门赛诺邦格生物科技股份有限公司 含氮的阳离子脂质及其应用
CN113999128B (zh) * 2021-11-25 2024-05-10 苏州科锐迈德生物医药科技有限公司 脂质化合物及基于其的脂质载体、核酸脂质纳米粒组合物和药物制剂
CN120097855A (zh) * 2021-12-31 2025-06-06 厦门赛诺邦格生物科技股份有限公司 一种侧链含功能性基团的阳离子脂质及其应用
CN114213347B (zh) * 2022-02-22 2022-05-20 中国科学院基础医学与肿瘤研究所(筹) 一种双价可电离脂质化合物、组合物及其应用
CN114213346B (zh) * 2022-02-22 2022-05-20 中国科学院基础医学与肿瘤研究所(筹) 一种双价可电离脂质化合物、组合物及其应用
CN118804743A (zh) * 2022-03-04 2024-10-18 益杰立科(上海)生物科技有限公司 靶向递送系统和方法
CN114874146B (zh) * 2022-03-25 2023-09-12 圣诺生物医药技术(苏州)有限公司 组氨酸脂质、组氨酸脂质纳米颗粒及其制备方法和应用
CN116354836A (zh) * 2022-03-25 2023-06-30 深圳市新合生物医疗科技有限公司 阳离子脂质化合物及其制备方法和应用、以及mRNA递送系统
EP4534525A4 (en) * 2022-06-02 2025-08-20 Xiamen Sinopeg Biotech Co Ltd CATIONIC LIPID BASED ON AMINO ACIDS CONTAINING UNSATURATED BONDS
CN115557851B (zh) * 2022-06-27 2023-04-18 上海云沂生物医药科技有限公司 一种氨基脂质、其合成方法、颗粒及用途
CN118265692B (zh) * 2022-09-09 2025-06-13 厦门赛诺邦格生物科技股份有限公司 一种碳核阳离子脂质
IL321425A (en) 2022-12-23 2025-08-01 Biontech Delivery Tech Gmbh compound
WO2024160826A1 (en) 2023-01-31 2024-08-08 BioNTech SE Compositions and methods
CN116143707B (zh) * 2023-02-24 2024-04-19 山东大学 一种碱基可电离脂质及其制备方法与应用
CN117384055B (zh) * 2023-04-27 2024-11-19 仁景(苏州)生物科技有限公司 用于递送治疗剂的可电离脂质及其用途
EP4719352A1 (en) 2023-05-31 2026-04-08 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
EP4727917A1 (en) * 2023-06-13 2026-04-22 Ramot at Tel-Aviv University Ltd. Biodegradable carbamate lipids with increased stability
WO2025027019A1 (en) 2023-07-31 2025-02-06 BioNTech SE Method of determining nucleic acid concentration in aqueous solution or dispersion
CN117137885A (zh) * 2023-08-29 2023-12-01 浙江大学 一种基于米屈肼衍生物的脂质纳米颗粒及其应用
WO2025064850A1 (en) 2023-09-22 2025-03-27 BioNTech SE Rna constructs with n-terminal degrons to enhance an immune response
TW202527962A (zh) 2023-10-31 2025-07-16 德商拜恩技術股份公司 粒子、組合物及方法
FR3155424A1 (fr) 2023-11-15 2025-05-23 BioNTech SE Compositions immunogènes contre le sars-cov-2
WO2025106754A1 (en) 2023-11-15 2025-05-22 BioNTech SE Coronavirus vaccine
WO2025133105A1 (en) 2023-12-21 2025-06-26 Biontech Delivery Technologies Gmbh Compositions and methods
AU2024413489A1 (en) * 2023-12-29 2026-07-16 Samyang Biopharm Corporation Nanoparticle composition for drug delivery
WO2025149492A1 (en) 2024-01-08 2025-07-17 BioNTech SE Rna encoding an immune inhibitory il-1 family member
WO2025160118A1 (en) * 2024-01-22 2025-07-31 The Trustees Of The University Of Pennsylvania Compositions and methods for hematopoietic stem cell (hsc) targeted delivery of therapeutic agents
WO2025176732A1 (en) 2024-02-20 2025-08-28 BioNTech SE Compositions and methods
WO2025215636A1 (en) 2024-04-08 2025-10-16 Yeda Research And Development Co. Ltd. Anti-defense system polypeptides and uses thereof
WO2025228979A1 (en) 2024-04-30 2025-11-06 Neovac Ltd. Lipids nanoparticle formulations suitable for lung targeting
WO2025245869A1 (zh) * 2024-05-31 2025-12-04 清华大学 含有精氨酸结构的可电离脂质分子、包含其的脂质纳米颗粒及其用途
WO2025261607A1 (en) 2024-06-21 2025-12-26 BioNTech SE Particles, compositions and methods
WO2026003582A2 (en) 2024-06-27 2026-01-02 Axelyf ehf. Lipids and lipid nanoparticles
WO2026009227A1 (en) 2024-07-04 2026-01-08 Yeda Research And Development Co. Ltd. Compositions for downregulating zeb2 in macrophages and uses thereof
WO2026013059A1 (en) 2024-07-08 2026-01-15 Neovac Ltd. Nanoparticle formulations for treatment of inflammations
WO2026021698A1 (en) 2024-07-23 2026-01-29 BioNTech SE Nucleic acid particle
WO2026047603A1 (en) 2024-08-28 2026-03-05 BioNTech SE Sars-cov-2 immunogenic compositions
WO2026047148A1 (en) 2024-08-29 2026-03-05 BioNTech SE Minimal polypeptide-encoding rnas
WO2026057626A1 (en) 2024-09-11 2026-03-19 BioNTech SE Peptidoglycan hydrolases having multiple enzymatically active domains
WO2026057625A1 (en) 2024-09-11 2026-03-19 BioNTech SE Peptidoglycan hydrolases having a chap domain with engineered active site
WO2026068864A1 (en) 2024-09-30 2026-04-02 BioNTech SE Engineered ch1 and cl domains for the prevention of chain mispairing
WO2026082899A2 (en) 2024-10-16 2026-04-23 BioNTech SE Rna for preventing or treating tuberculosis
WO2026109749A1 (en) 2024-11-24 2026-05-28 Neovac Ltd. Ionizable lipids suitable for nucleic acid delivery
WO2026109750A1 (en) 2024-11-24 2026-05-28 Neovac Ltd. Ionizable lipids useful in nucleic acid delivery
WO2026119817A1 (en) 2024-12-02 2026-06-11 BioNTech SE Agents and methods for targeted delivery of immune effector cells
WO2026125590A1 (en) 2024-12-13 2026-06-18 BioNTech SE Measuring nucleic acid integrity
WO2026125598A1 (en) 2024-12-13 2026-06-18 BioNTech SE Measuring nucleic acid integrity
WO2026148356A1 (en) 2025-01-06 2026-07-09 BioNTech SE Coronavirus and influenza immunogenic combinations
WO2026150132A1 (en) 2025-01-12 2026-07-16 BioNTech SE Combination therapy comprising an rna cancer vaccine and a multispecific binding agent targeting pd-1/pd-l1 and vegf/vegfr for cancer treatment
WO2026162682A1 (en) 2025-01-29 2026-08-06 BioNTech SE Compositions for delivery of plasmodium rh5 antigens and related methods
WO2026162552A1 (en) 2025-01-31 2026-08-06 BioNTech SE Agents and methods for targeted delivery to cells

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL58413C (cg-RX-API-DMAC10.html) * 1941-12-04
US3703554A (en) * 1969-07-22 1972-11-21 Scm Corp Terpenylamino ethers and thioethers
GB1367089A (en) * 1970-07-23 1974-09-18 Marumo H Surface modifier for synthetic high polymers
US4034040A (en) * 1971-05-24 1977-07-05 Pfizer Inc. Xylene-diamines as antiviral agents
FR2687398B1 (fr) * 1992-02-17 1994-04-29 Oreal Monomeres betauiniques, polymeres correspondants ainsi que leur utilisation, et procedes de preparation y relatifs.
JP3544429B2 (ja) * 1996-04-25 2004-07-21 三菱製紙株式会社 可逆性感熱記録材料
WO2006111982A1 (en) 2005-04-21 2006-10-26 National Research Development Corporation A process for producing modified reconstituted sendai viral envelope specific for drug and/or gene delivery to liver cells
EP3699172A3 (en) 2008-11-10 2020-11-18 Arbutus Biopharma Corporation Novel lipids and compositions for the delivery of therapeutics
CN102665761A (zh) 2009-11-04 2012-09-12 玛瑞纳生物技术有限公司 活性产生递送分子
WO2013016058A1 (en) 2011-07-22 2013-01-31 Merck Sharp & Dohme Corp. Novel bis-nitrogen containing cationic lipids for oligonucleotide delivery
TW201726599A (zh) * 2012-07-06 2017-08-01 協和醱酵麒麟有限公司 陽離子性脂質
CA2953341C (en) * 2014-06-25 2023-01-24 Acuitas Therapeutics Inc. Lipids and lipid nanoparticle formulations for delivery of nucleic acids
WO2016021673A1 (ja) 2014-08-06 2016-02-11 協和発酵キリン株式会社 small RNA含有医薬組成物の薬効を予測する方法
WO2016176330A1 (en) * 2015-04-27 2016-11-03 The Trustees Of The University Of Pennsylvania Nucleoside-modified rna for inducing an adaptive immune response
CN108368028B (zh) 2015-10-28 2021-09-03 爱康泰生治疗公司 用于递送核酸的新型脂质和脂质纳米颗粒制剂

Similar Documents

Publication Publication Date Title
JP6018644B2 (ja) 1−[2−(2,4−ジメチル−フェニルスルファニル)−フェニル]−ピペラジンの製造方法
ES2567047T3 (es) Derivados de pirimidina anti-virales
ES2396267T3 (es) Procedimiento para sintetizar compuestos útiles para el tratamiento de la hepatitis C
JP2010516635A5 (cg-RX-API-DMAC10.html)
JP2011219498A5 (cg-RX-API-DMAC10.html)
ES2496592T3 (es) Proceso para la preparación de Imatinib y compuestos intermedios del mismo
WO1996018608A1 (en) Aniline derivatives having nitrogen monoxide synthase inhibitory activity
JP6832946B2 (ja) キナーゼ阻害剤およびその中間体の調製方法
JP2022512736A5 (cg-RX-API-DMAC10.html)
RU2014145819A (ru) Бициклическое соединение
CZ20024191A3 (cs) Vodný roztok meloxicamu
JP2009528318A5 (cg-RX-API-DMAC10.html)
RU2017130474A (ru) Замещенные триаозлы и способы, касающиеся их
JP2017519796A5 (cg-RX-API-DMAC10.html)
RU2008105304A (ru) Соединение бензоимидазола, способное к ингибированию простагландин-d-синтетазы
CA2590479A1 (en) Triazole substituted aminobenzophenone compounds
JP2021514399A5 (cg-RX-API-DMAC10.html)
KR20180005214A (ko) 질소 머스타드 유도체의 제조 방법
EP3628374B1 (en) Bcl-3 inhibitors
JP2020518621A5 (cg-RX-API-DMAC10.html)
Nakamura et al. Novel 6-hydroxy-3-morpholinones as cornea permeable calpain inhibitors
JP2022527213A5 (cg-RX-API-DMAC10.html)
JP2005508382A5 (cg-RX-API-DMAC10.html)
AR024741A1 (es) Derivados de la diacilhidrazina, un procedimiento para su preparacion, el empleo de los mismos en la preparacion de composiciones farmaceuticas y en losprocesos patologicos que se propagan o mantienen por angiogenesis, y las composiciones farmaceuticas que las contienen.
ES2245639T3 (es) Compuestos 1,2,3,4-tetrahidro-1-naftalenamina utiles en terapia.